AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
171.56
-1.37 (-0.79%)
At close: 4:00PM EDT

171.56 0.00 (0.00%)
After hours: 4:45PM EDT

Stock chart is not supported by your current browser
Previous Close175.11
Open173.10
Bid171.60 x 500
Ask172.19 x 100
Day's Range170.58 - 173.47
52 Week Range152.16 - 201.23
Volume2,279,036
Avg. Volume5,263,433
Market Cap114.648B
Beta1.71
PE Ratio (TTM)63.78
EPS (TTM)2.69
Earnings DateApr 24, 2018
Forward Dividend & Yield5.28 (3.08%)
Ex-Dividend Date2018-05-16
1y Target Est195.14
Trade prices are not sourced from all markets
  • Benzinga4 hours ago

    The Week Ahead In Biotech: PDUFA Dates, IPOs And More

    The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is almost flat for the week after adding about 5 percent in the week ended April 13. Will the following catalytic events lead to a resumption ...

  • Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?
    Zacks7 hours ago

    Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?

    While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

  • 3 Stocks You Can Safely Own Until 2030
    Motley Fool9 hours ago

    3 Stocks You Can Safely Own Until 2030

    If you're looking for stocks built to last, check out Amgen, Berkshire Hathaway, and Aptiv.

  • PR Newswireyesterday

    Amgen Announces Webcast Of 2018 First Quarter Financial Results

    THOUSAND OAKS, Calif., April 19, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its first quarter 2018 financial results on Tuesday, April 24, 2018, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors.

  • Gilead Sciences Expects Decline in Earnings in Fiscal 2018
    Market Realistyesterday

    Gilead Sciences Expects Decline in Earnings in Fiscal 2018

    Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.

  • Moody's2 days ago

    Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising

    The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.

  • Gilead Sciences May Witness Significant Drop in Revenues in 2018
    Market Realist2 days ago

    Gilead Sciences May Witness Significant Drop in Revenues in 2018

    Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...

  • What Analysts Recommend for Gilead Sciences in April 2018
    Market Realist2 days ago

    What Analysts Recommend for Gilead Sciences in April 2018

    In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.

  • ETF Trends2 days ago

    Big Biotech ETF Can Bounce Back

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and other biotechnology assets have recently been slumping, but some analysts believe big biotechnology ...

  • Amgen's Aimovig Reduces Episodic Migraine in 30% Patients
    Zacks2 days ago

    Amgen's Aimovig Reduces Episodic Migraine in 30% Patients

    Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.

  • PR Newswire3 days ago

    Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures

    THOUSAND OAKS, Calif., April 17, 2018 /PRNewswire/ -- Amgen (AMGN) today announced full results from the Phase 3b LIBERTY trial of Aimovig™ (erenumab) in episodic migraine patients who had previously failed two to four preventive treatments, due to lack of efficacy or to intolerable side effects.1 The data, which will be presented at the 70th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, show the potential of Aimovig as an effective preventive treatment option for these patients, who have tried several treatment options without gaining relief. Aimovig is the only investigational fully human monoclonal antibody under regulatory review that was designed to selectively block the calcitonin gene-related peptide (CGRP) receptor, which plays a critical role in migraine activation.

  • Reuters3 days ago

    Amgen's Aimovig halved migraine days in 30 pct of trial patients

    A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday. The 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects. "This is a trial in really difficult to treat patients," professor Uwe Reuter, trial investigator and managing medical director at Charité Universitätsmedizin in Berlin, told Reuters in a telephone interview.

  • Risankizumab Could Be AbbVie’s Long-Term Growth Driver
    Market Realist3 days ago

    Risankizumab Could Be AbbVie’s Long-Term Growth Driver

    In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.

  • How AbbVie’s Humira Performed in 4Q17 and 2017
    Market Realist4 days ago

    How AbbVie’s Humira Performed in 4Q17 and 2017

    AbbVie’s (ABBV) Humira generated revenue of $4.9 billion in 4Q17 and $4.3 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~4% growth quarter-over-quarter. In 4Q17, in US and international markets, Humira reported revenue of $3.3 billion and $1.6 billion, respectively, marking ~15.1% and ~11.7% growth YoY.

  • How AbbVie Performed in 4Q17 and Fiscal 2017
    Market Realist4 days ago

    How AbbVie Performed in 4Q17 and Fiscal 2017

    AbbVie (ABBV) generated revenue of $7.7 billion in 4Q17 and $6.8 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~11% growth quarter-over-quarter. AbbVie reported revenue of $28.2 billion in fiscal 2017 and $25.6 billion in fiscal 2016, representing ~10% YoY growth.

  • Analysts’ Recommendations for Johnson & Johnson on April 16
    Market Realist4 days ago

    Analysts’ Recommendations for Johnson & Johnson on April 16

    Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.

  • Exploring the Growth Trajectory of Amgen’s Repatha
    Market Realist8 days ago

    Exploring the Growth Trajectory of Amgen’s Repatha

    Amgen (AMGN) is one of the world’s leading biotechnology companies, with a presence in ~100 countries. Amgen’s Repatha is a human monoclonal antibody that inhibits proprotein convertase kexin type nine (or PCSK9). The drug has been approved in more than 50 regions, including the United States, Japan, Canada, and the European Union.

  • Incyte Expected to Report Robust Revenue Growth in Fiscal 2018
    Market Realist9 days ago

    Incyte Expected to Report Robust Revenue Growth in Fiscal 2018

    In 2017, Incyte (INCY) reported total revenues of close to $1.5 billion, which was year-over-year (or YoY) growth of around 38.9%. The company earned revenues close to $1.1 billion from the sale of Jakafi, a JAK1/JAK2 inhibitor, in the US, and $152 million as royalties received from Novartis (NVS) on the sale of Jakafi, marketed as Jakavi, in international markets. Wall Street analysts have projected Incyte’s fiscal 2018 revenues to be close to $1.8 billion, which is a YoY rise of around 16.9%.

  • What Analysts Recommend for Incyte in April 2018
    Market Realist9 days ago

    What Analysts Recommend for Incyte in April 2018

    On April 6, 2018, Incyte (INCY) reported unfavorable results from its phase 3 ECHO-301/KEYNOTE-252 study, which evaluated the potential of the company’s investigational therapy, epacadostat, combined with Merck’s (MRK) Keytruda, in patients suffering from unresectable or metastatic melanoma as compared to those treated with Keytruda monotherapy. The trial failed to meet its first primary endpoint of improvement in progression-free survival and is also not expected to meet the second primary endpoint of overall survival. This news has had a drastic impact on Incyte’s stock, which fell ~22.9% from $83.07 on April 5, 2018, to $64.02 on April 6, 2018, and reduced the company’s market capitalization by approximately $3.5 billion.

  • Amgen Stock Performance in 1Q18
    Market Realist10 days ago

    Amgen Stock Performance in 1Q18

    Amgen (AMGN) is a biotechnology company with headquarters in Thousand Oaks, California. Amgen discovers, develops, and delivers drugs for various therapeutic areas, including cardiovascular, neuroscience, and oncology.

  • Reuters10 days ago

    Rhode Island governor says Amgen will build second plant in state

    Amgen Inc will build a $165 million next-generation biopharmaceutical plant adjacent to its West Greenwich, Rhode Island manufacturing campus, the state governor's office told Reuters on Tuesday. The plant will use Amgen's new flexible and reconfigurable technology, part of the company's ongoing efforts to control costs. Amgen, headquartered in Thousand Oaks, California, said in January it would locate the new plant in the United States, due in part to a lower effective tax rate stemming from U.S. tax reform.

  • PR Newswire10 days ago

    Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant

    THOUSAND OAKS, Calif., April 10, 2018 /PRNewswire/ -- Amgen (AMGN) today announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I. The new plant, the first of its kind in the United States (U.S.), will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the U.S. and global markets. A next-generation biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built in half the construction time with approximately one half of the operating cost of a traditional plant. Next-generation biomanufacturing plants require a smaller manufacturing footprint and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $13.67 billion.

  • PR Newswire11 days ago

    Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018

    THOUSAND OAKS, Calif., April 9, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Data spans Amgen's early pipeline, including the first presentation of data for its most advanced chimeric antigen receptor (CAR) T cell therapy programs, targeting DLL3 in small cell lung cancer and FLT3 in acute myeloid leukemia (AML). In addition, pre-clinical data for Amgen's DLL3 CAR T cell therapy and bispecific CD19-directed CD3 T cell engager (BiTE®) program will be featured in an oral presentation.